Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants.

Yu, Yunfang; Lin, Dagui; Li, Anlin; Chen, Yongjian; Ou, Qiyun; Hu, Hai; Yao, Herui

Yu, Yunfang; Lin, Dagui; Li, Anlin; Chen, Yongjian; Ou, Qiyun; Hu, Hai; Yao, Herui.

Afiliación

Yu Y; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Lin D; Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Li A; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Chen Y; Guangdong Medical University, Zhanjiang, China.
Ou Q; Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Hu H; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Yao H; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

JAMA Netw Open ; 3(6): e205837, 2020 06 01.

Article en En | MEDLINE | ID: mdl-32530468

Asunto(s)

Antineoplásicos Inmunológicos/uso terapéutico; Antígeno Ca-125/genética; Proteínas de la Membrana/genética; Neoplasias/tratamiento farmacológico; Neoplasias/genética; Anciano; Biomarcadores de Tumor/genética; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Carcinoma de Pulmón de Células no Pequeñas/genética; Femenino; Variación Genética; Humanos; Estimación de Kaplan-Meier; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Masculino; Melanoma/tratamiento farmacológico; Melanoma/genética; Persona de Mediana Edad; Supervivencia sin Progresión; Modelos de Riesgos Proporcionales; Tasa de Supervivencia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antígeno Ca-125 / Antineoplásicos Inmunológicos / Proteínas de la Membrana / Neoplasias Tipo de estudio: Risk_factors_studies / Systematic_reviews Idioma: En Revista: JAMA Netw Open Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google